Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (348)	3/26/2003 11:37:48 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 625

Me neither. It sounds like the agreement allowed ABT to enter into licensing agreements, even without CAT's knowledge, if in good faith they were considered necessary to commercialize H freely, and that such royalties would offset CAT royalties $ for $ , but not below a minimum. You would think this would not be the case if, in the original agreement, CAT agreed to defend H IP which they probably also did. In any event, looks like abt may have skinned the cat. Experienced leadership got to CAT too late. This makes Chambre's efforts to clean up the world's phage IP look wasted. What a shame if this is the ultimate result for CAT.